Hitomi Tamura

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 926 citations · Full text

Medicine, Oncology, Pharmacology +17

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2019 · 69 citations

Medicine, Oncology, Pharmacology +16

A multicentre confirmatory single‐arm trial of the safety and efficacy of a transanal drain for prevention of anastomotic leakage after surgery for rectal cancer

Yuji Nishizawa, Hideaki Nishigori, Yuichiro Tsukada et al. · Colorectal Disease · 2021 · 12 citations

Medicine, Oncology, Surgery +16

A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604)

Akihito Kawazoe, Daisuke Takahari, Keisho Chìn et al. · Gastric Cancer · 2020 · 11 citations · Full text

Medicine, Oncology, Surgery +6

Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603).

Kohei Shitara, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 10 citations

Pharmacy, Pharmacology, Cancer Drug Toxicity Management +9